Skip to main content
. 2019 Apr 4;10:664. doi: 10.3389/fimmu.2019.00664

Figure 1.

Figure 1

SLPI inhibits BzATP-mediated IL-1β release by U937 cells. Human monocytic U937 cells were primed with LPS (1 μg/ml, for 5 h) and further stimulated with 2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate triethylammonium salt (BzATP; 100 mM) or nigericin (50 μM) for 30 min. The concentration of IL-1β in cell culture supernatants was measured by ELISA. The mRNA expression of pro-IL-1β was assessed by real-time PCR. (A) SLPI dose-dependently and effectively inhibited the BzATP-mediated IL-1β release. (B) The LPS-induced mRNA levels of pro-IL-1β were not changed upon stimulation with SLPI. AU, arbitrary units (C) The treatment with apyrase (0.5 U/ml) fully abolished the BzATP-mediated IL-1β release. (D) The nigericin-mediated IL-1β secretion was not affected in the presence of SLPI. *p ≤ 0.05 significantly different compared to cells stimulated with LPS and BzATP (A,C) or LPS alone (D). Experimental groups were compared by Kruskal-Wallis test followed by Mann-Whitney rank sum test.